In a much-anticipated decision, the FDA approved Eli Lilly's donanemab. This anti-amyloid antibody is the third drug intended to alter the progression of Alzheimer's disease treatment. This approval will intensify the competition between Eli Lilly's Donanemab and Biogen and Eisai's ADUHELM (aducanumab), and LEQEMBI (lecanemab).
LAS VEGAS , July 8, 2024 /PRNewswire/ -- Alzheimer's disease, the most common type of dementia, is a progressive neurodegenerative disorder with a multifactorial pathogenesis. It is characterized by a gradual decline in cognitive and functional abilities, with individuals eventually losing the ability to undertake everyday tasks and function independently. As per DelveInsight analysis, in 2023, the total diagnosed prevalent cases of Alzheimer's disease in the 7MM were 15.
4 million . These cases are projected to increase further during the forecast period (2024–2034). In 2023, the United States had the highest proportion of diagnosed prevalent cases of Alzheimer's disease among the 7MM, comprising approximately 41% of the total cases.
Conversely, the United Kingdom had the lowest share, representing nearly 4% of the total diagnosed prevalent cases of Alzheimer's in 2023. As the size and proportion of the US population aged 65 and older continue to increase, the number of Americans with Alzheimer's or other dementias will grow. While there is no cure for Alzheimer's disease at present, starting treatment early and maintaining it consistently is crucial.
